Inborn errors of metabolism

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024
Knowledge, Division, Endocrinology, T2D, Inborn errors of metabolism, Metabolism, Education, Treatment, Insulin, Physician, Quality of life, ATTD, Faculty, DNP, University, Type 2 diabetes, EMBC, MDI, Fortezza, Case Western Reserve University, Patient, D.O, Poster, Needlestick injury, Risk, Lipohypertrophy, Obesity, Research, Fortezza da Basso, Time in Europe

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.

Key Points: 
  • Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
  • Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D).
  • The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI).
  • Another poster highlights data showing that in individuals with type 2 diabetes, insulin pump therapy eases constraints imposed by diabetes management and improves quality of life.

J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board

Retrieved on: 
Tuesday, February 27, 2024
Rubius, Odyssey, Senior, Inborn errors of metabolism, Investment, Drug development, Growth, Sale, IPO, University, Intuitive Surgical, Neurodegenerative disease, Analog Devices, National academy, J. P. Morgan, MIT, Genetic distance, American Philosophical Society, Business development, Journal, Therapy, Imatinib, SRL Diagnostics, MidOcean Partners, Distinction, Laboratory, Cornell University, Drug discovery, Weill Cornell Medicine, Provost, Panasonic Executive Partner, Abbott Laboratories, Flagship, Novartis, Medtronic, MACP, Harvard Medical School, Nilotinib, American Academy, Yale School of Medicine, JPMorgan Chase, AI, MD, Flagship Pioneering, Harvard University, MassMutual, Executive, Cancer, Management

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital today announced the addition of David Epstein to its Healthcare Advisory Board.
  • Mr. Epstein will now advise the J.P. Morgan Life Sciences Private Capital team.
  • The J.P. Morgan Life Sciences Private Capital team leverages JPMorgan Chase's scale, resources, data assets and healthcare expertise and sits within J.P. Morgan Private Capital, a venture and growth equity investment platform that is part of J.P. Morgan Asset Management.
  • The platform finances the continued growth of private companies and taps into significant pre-IPO value creation opportunities in the consumer and technology, and life sciences sectors.

National Academy of Medicine Member New President of The Obesity Society

Retrieved on: 
Thursday, February 1, 2024
Bias, The Obesity Society, Medical school, Growth, University, Metabolism, Science, Obesity, Duke University Hospital, Division, Society, National academy, Patient, Inborn errors of metabolism, Columbia University, Wellness, Executive Committee, ARD, Obesity medicine, Harvard Medical School, Education, Health equity, Doctor of Philosophy, Health, Cornier, Cedars-Sinai Medical Center, Clinical research, Internal medicine

ROCKVILLE, Md. , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.

Key Points: 
  • , Feb. 1, 2024 /PRNewswire/ -- A member of the National Academy of Medicine is the new president of The Obesity Society (TOS), the organization announced today.
  • He also co-directs the Atrium Health Wake Forest Baptist Weight Management Center, where he oversees medical weight management programs.
  • "I am honored to serve as president of TOS during such a transformative time in the field of obesity.
  • The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects.

MGI Empowers the Completion of Nearly 60,000 Samples for The Million Microbiome of Humans Project

Retrieved on: 
Monday, May 15, 2023
University College London, Karolinska Institute, DNA, Disease, University, Partnership, Institute of technology, Food, COVID-19, INRAE, Research, Biomedical Research, DNB, USD, De novo, Organization, Inborn errors of metabolism, United Nations Research Institute for Social Development, Technical University of Denmark, Cancer, Medicine, Copenhagen, University of Copenhagen Faculty of Health and Medical Sciences, Ecology, Health, Metagenomics, Microbiology, MGI, Virulence, Fine chemical, Pharmaceutical industry, Antibiotics, Environment

Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."

Key Points: 
  • Despite a brief interruption by the COVID-19 pandemic, we are delighted to see such a monumental milestone merely four years into the project."
  • Advances in genome sequencing has enabled researchers to better characterize the composition of the microbiome through identification of unculturable microbes.
  • Besides human microbiome, it is highly applicable in agricultural microbiome studies, environmental microbiome studies, pathogen surveillance and identification, and monitoring of antimicrobial resistance genes.
  • MGISP-960's fully automatic operation design allows DNA extraction of 50,000 samples per year and library preparation of 25,000 samples per year.

Dalriada further strengthens small molecule discovery expertise with appointment of veteran Dr. Frosty Loechel as SVP Biology, Discovery Strategy group

Retrieved on: 
Wednesday, April 19, 2023
Lundbeck, Dál Riata, CNS, Inborn errors of metabolism, Thermo Fisher Scientific, BioImage, Drug discovery, Biology, SVP, Pharmacology, Pharmaceutical industry

TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today the appointment of Frosty Loechel, Ph.D. as SVP Biology, Discovery Strategy group.

Key Points: 
  • TORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today the appointment of Frosty Loechel, Ph.D. as SVP Biology, Discovery Strategy group.
  • The appointment confirms Dalriada’s ambition to remain at the forefront of expertise and capabilities in small molecule drug discovery with its pioneering and agile TURN-KEY™ model.
  • At Dalriada, Dr. Loechel will be responsible for scientific strategy in biology for drug discovery programs.
  • Welcoming Dr. Loechel to the Company, Dalriada’s Chief Executive and co-founder, Dr. Diana Kraskouskaya commented: “I am delighted to have Dr. Loechel join Dalriada.

Premier Research Fortifies Cell and Gene Therapy Leadership Team, Strengthening End-to-End Capabilities in Complex Asset Development

Retrieved on: 
Monday, April 17, 2023
Pharmacy, Central nervous system, CGT, Gene, Quality by design, Pediatrics, CMC, NMES, Strategic planning, RNA, CNS, DSM-IV codes, Metabolism, Inborn errors of metabolism, Dermatology, Documentation, FACMG, Aloba, Hematology, Regulatory affairs, Cardiology, Research, TGA, FDA, Neurology, Meyer, Safety, Medical device, Pharmaceutical industry, EU, Cell

MORRISVILLE, N.C., April 17, 2023 /PRNewswire/ -- Premier Research announced today the addition of Kenneth Ndugga-Kabuye, M.D., FACMG, as VP, Cell & Gene Therapy to the strategic Cell & Gene Therapy (CGT) Leadership Team. Ndugga-Kabuye joins experts Jessica Merryfield, Executive Director, Cell & Gene Therapy, Olu Aloba, Ph.D., VP, CMC Services and Greg Meyer, VP, Regulatory Affairs in addressing the complexities of CGT development, as evolving regulatory receptivity creates a supportive environment for innovation.

Key Points: 
  • Cell and Gene Therapy Expert Dr. Kenneth Ndugga-Kabuye to Lead
    Clinical Strategy With Collaboration From Operations, CMC and Regulatory Experts
    MORRISVILLE, N.C., April 17, 2023 /PRNewswire/ -- Premier Research announced today the addition of Kenneth Ndugga-Kabuye, M.D., FACMG, as VP, Cell & Gene Therapy to the strategic Cell & Gene Therapy (CGT) Leadership Team.
  • "The speed at which agency guidance is changing, coupled with complicated cell and gene therapy study logistics, is creating demand for early, in-depth strategic planning," Premier Research Chief Operating Officer Michael Arlotto, Ph.D., said.
  • "Cell and gene therapy approval pathways are highly variable among regulatory agencies globally," Ndugga-Kabuye said.
  • Jessica Merryfield, Executive Director, Cell & Gene Therapy, who has more than 20 years of clinical research experience, including more than 10 years specializing in CGT.

Cell Metabolism Features the AMP® Type 2 Diabetes Knowledge Portal as a Valuable Tool for Biomedical Researchers

Retrieved on: 
Tuesday, April 4, 2023
Research, Technology, Genetics, Diabetes, Health Technology, Software, Philanthropy, Health, Foundation, Science, Knowledge, NIDDK, Business development, FNIH, Cell Metabolism, Partnership, American Diabetes Association, Drug development, Broad Institute, University, JDRF, Type 2 diabetes, National Institute of Diabetes and Digestive and Kidney Diseases, Pfizer, University of California, San Diego, Risk, MIT, Doctor of Philosophy, Harvard University, Bangladesh Technical Education Board, Development, Inborn errors of metabolism, Kidney, MD, Patient, Liver, Eli Lilly and Company, Merck, Digestive, T2D, NIH, Disease, Pharmaceutical industry, Sanofi

The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal ( T2DKP ) is featured in a Cell Metabolism article published today.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) announces that the Type 2 Diabetes Knowledge Portal ( T2DKP ) is featured in a Cell Metabolism article published today.
  • The T2DKP is a publicly available source of genetic datasets dedicated to type 2 diabetes and its related traits.
  • The AMP T2D Knowledge Portal provides software infrastructure to support, combine, and harmonize more than 300 anonymized datasets from research studies around the world.
  • An innovative feature of the portal allows the retrieval of genetic data that complies with European Union data protection requirements.

Eating Almonds Before Meals Improved Blood Sugar Levels in Some People with Prediabetes

Retrieved on: 
Wednesday, March 22, 2023
Breakfast, Exercise, Hyperglycemia, Insulin, Food, Diet, Zinc, Shoulder, Diabetes, Prevalence, Public, Magnesium, Glucose, Glucagon, DV, OGTT, Lipid, Vitamin E, C-reactive protein, Nutrient, Meal, Head, Research, Medicine, Almond, Prediabetes, Hormone, Human, A1C, Inborn errors of metabolism, Waist, Blood, National Diabetes Education Program, Professor, CGMS, Risk, C-peptide, Lunch, Overweight, Clutch (eggs), PPHG, Body mass index, Hunger, Potassium, Birth control, Dietary supplement, Pharmaceutical industry, Medical device, Obesity, Proinsulin, Endocrinology

MODESTO, Calif., March 22, 2023 /PRNewswire/ -- Two new research studies1-2 with almonds, one conducted over three days and the other over three months, demonstrated benefits to blood sugar control for Asian Indians with prediabetes and overweight/obesity – and the three-month almond intervention broke new ground, reversing prediabetes, or glucose intolerance, to normal blood sugar levels in nearly one quarter (23.3%) of the people studied.

Key Points: 
  • The findings complement the breadth of research on different populations on how almonds support healthy blood sugar as part of a balanced diet.
  • "Results from our studies indicate almonds might be a key differentiator in helping regulate blood glucose levels as part of a dietary strategy.
  • Eating 20 g of almonds 30 minutes before an oral glucose load showed a significant decrease in blood sugar and hormones.
  • These substantial metabolic improvements led to nearly one-fourth (23.3%) of the prediabetes study participants returning to normal blood glucose regulation.

CENTOGENE to Participate in Upcoming Conferences in March

Retrieved on: 
Wednesday, March 8, 2023
Journal of Inherited Metabolic Disease, Myotonia congenita, Genetic testing, Congress, LabEx ReFi - European Laboratory on Financial Regulation, Conference, Inborn errors of metabolism, Diagnosis, Innovation, Pharmaceutical industry, Online shopping, Pharma

CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities.

Key Points: 
  • CENTOGENE representatives will be attending events in Brazil, the U.S., Saudi Arabia, Thailand, and the U.K. and will be available to discuss Pharma, CRO, and Diagnostic collaboration opportunities.
  • Please see additional details below:
    To learn more about the 3rd Brazilian Congress of Neurogenetics 2023 and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3KK0jgi ).
  • To learn more about the 6th Asian Congress on Inherited Metabolic Diseases 2023 and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3ZpRrRe ).
  • To learn more about the European Laboratory Research & Innovation Group’s (ELRIG) Research & Innovation 2023 conference and set up an in-person meeting with the CENTOGENE team, please visit the event webpage ( https://link.centogene.com/3YKdpOh ).

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, February 28, 2023
Sequence, American College, Doctor of Philosophy, De novo, University, MD, Pancreatic cancer, PDS5B, Patient, Disease, GeneDx, Partnership, Phenotype, Research, Standard of care, Rare, Mutation, Multiple, WGS, Salt Palace, Inborn errors of metabolism, Medical genetics, American College of Medical Genetics and Genomics, Therapy, PDS5A, ACMG, Rare disease, Columbia University, Metabolism, Rare Disease Day, University of Washington, Seizure, Vaccine, Medical imaging, Ovary, Genomics

GeneDx is a leader in rare disease diagnosis and has spent the last 20 years building one of the largest rare disease datasets in the genomics industry, including data from more than 400,000 clinical exomes. These data play a critical role in the company’s research -- and in the insights it delivers to providers -- to enable the delivery of informed, patient-centered care. It also supports the identification, discovery and development of creating therapeutics to manage and treat rare genetic diseases.

Key Points: 
  • The announcement coincides with Rare Disease Day and is just the latest example of the company’s dedication to eradicating the multi-year diagnostic odyssey faced by many families seeking clinical diagnoses for critically ill patients.
  • GeneDx is a leader in rare disease diagnosis and has spent the last 20 years building one of the largest rare disease datasets in the genomics industry, including data from more than 400,000 clinical exomes.
  • “While today is officially recognized as Rare Disease Day, every day is rare disease day for us as we work tirelessly to shorten and ultimately end the diagnostic odyssey,” said Katherine Stueland, GeneDx President and CEO.
  • “With the increasing focus on patients with rare disease, we’re proud to bolster the medical community’s ability to diagnose disease more accurately and rapidly.